The American Joint Replacement Registry (AJRR) has rounded out its 2016 Board of Directors with the addition of Douglas E. Padgett, M.D. as an American Academy of Orthopaedic Surgeons (AAOS) representative and Yvonne Bokelman as an AdvaMed representative. The AJRR Executive Committee has a new member as well: Blair Fraser is the new AdvaMed representative. He previously served on the AJRR Board of Directors without an executive role.
Doug Padgett, M.D., Yvonne Bokelman Join AJRR Board

“The Board of Directors provides an excellent balance between the different parties interested in our Registry data, ” said AJRR executive director Jeffrey P. Knezovich, in the January 28, 2016 news release. “Without the guidance and perspective of diverse stakeholders, our organization would not be nearly as strong. Our new Board members will be a great help in carrying out the best interests of both their specific organization and the AJRR.”
E. Anthony Rankin, M.D., AAOS representative and Pamela L. Plouhar, Ph.D., AdvaMed representative are stepping down from the Board.
“As 2015 came to an end, so did the terms of two influential Board of Directors members. Dr. E. Anthony Rankin was the only remaining member from the original Board, and as such, has provided AJRR with a vast amount of assistance, ” continued Knezovich. “Dr. Pamela L. Plouhar represented industry well and guided us in establishing a valuable business report and plan, while providing leadership from the perspective of the medical device industry. We wholeheartedly thank both of these leaders for their individual support and contributions through the years.”
Yvonne Bokelman told OTW, “Coming into this role, I am eager to be deeply involved in assisting the AJRR in realizing its vision of developing into the premiere U.S. joint replacement Registry. I believe as an orthopaedic industry representative, and with my expertise in market access/reimbursement and prior experiences in hospital administration, I will bring additional creative perspectives. I look forward to collaborating with other AJRR Directors, stakeholders and the AJRR staff in ensuring the growth and success of the Registry.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.